Phase II, Single-arm Study of Olaparib and Bevacizumab Combination Therapy in Relapsed Small Cell Lung Cancer Subjects With DNA Damage Response and the Repair Pathway Alteration, ATM Deficiency, SLFN11 Positive, or POU2F3 Positive
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Bevacizumab (Primary) ; Olaparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SUKSES-B2
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 29 Dec 2023 Status changed from recruiting to completed.
- 09 Nov 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.